SMRT Clinical Focus Session: MR Contrast: An Update on MRI Contrast Panel Discussion 2

SMRT Clinical Focus Session

MR Contrast: An Update on MRI Contrast Panel Discussion 2

Back to Program-at-a-Glance

Session Topic: SMRT Live Q&A 8

Session Sub-Topic: Clinical Focus Session - MR Contrast: An Update on MRI Contrast Panel Discussion 2

SMRT Ed Session

ORGANIZERS: Claire Mulcahy

SMRT Parallel Room 8 Live Q&A

Monday, 10 August 2020, 04:45 - 05:30 UTC

Moderators: Barbara Pirgousis

Session Number: SMRT-16

Overview
The safety of gadolinium (Gd) continues to be questioned especially with concerns around gadolinium deposition in the brain and body. The session will review current developments in contrast agent safety, including methods to reduce gadolinium dosage and the use of alternative contrast agents.

Target Audience
Radiographers, MR technologists, radiologists, clinicians, and scientists who utilise contrast agents for clinical or research applications

Educational Objectives
As a result of attending this course, participants should be able to:
1. Describe the perceived risks associated with gadolinium based contrast agents and review alternative contrast agent approaches.
2. Identify the minimum dosage of gadolinium based contrast agent recommended to ensure diagnostic value in MR images.
3. Review the usage of Ferumoxytol as a MR contrast agent in terms of sensitivity, availability and performance.

To Contrast or Not to Contrast, That Is the Question: A Pediatric Perspective

Michael Kean

Watch the Video

The presentation will cover the complex issues or GBCA elimination / dose reduction techniques and off-label applications in clinical pediatric MRI imaging.

The Why / When and How of these strategies will be covered based on our experiences gained over 5 years of Gd reduction scanning. Why we implemented our program 5 yrs ago and lessons we have learnt including the optimisation of imaging sequences, timing of post Gd injections. The Off-Label protocols using Hepatocyte contrast ( Primovist/Eovist ), protocols associated with using macrocyclic agents with age restrictions and a brief insight into the use of Ferumoxytol in children